drugset / Trial / NCT06844474
A Phase II Clinical Study of SHR-1826 for Injection in Patients With NSCLC
NaSingle-groupOpen-labelTreatment
Summary
This study is an open-label, multicenter Phase II clinical trial to evaluate the safety, tolerability and efficacy of SHR-1826 for injection in patients with NSCLC.
Timeline
- Start
- 2025-03-07
- Primary completion
- 2026-12
- Completion
- 2028-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SHR-1826 | Unknown | — | Intravenous |
| Background | Adebrelimab | Monoclonal antibody | — | Intravenous |
| Background | Bevacizumab | Monoclonal antibody | — | Intravenous |
| Background | SHR-8068 | Monoclonal antibody | — | Intravenous |